PHOSPHORUS
DEFICIT(HYPOPHOSPHATEMIA)
Hypophosphatemia is a
below-normal serum concentration of inorganic phosphorus. Although it often
indicates phosphorus deficiency, hypophosphatemia may occur under a variety of
cir-cumstances in which total body phosphorus stores are normal. Conversely,
phosphorus deficiency is an abnormally low content of phosphorus in lean
tissues and may exist in the absence of hypophosphatemia.
Hypophosphatemia may
occur during the administration of calories to patients with severe
protein-calorie malnutrition. It is most likely to occur with overzealous
intake or administration of simple carbohydrates. This syndrome can be induced
in anyone with severe protein-calorie malnutrition (eg, patients with anorexia
nervosa or alcoholism, or elderly debilitated patients unable to eat). As many
as 50% of patients hospitalized because of chronic alco-holism have
hypophosphatemia.
Marked hypophosphatemia may develop in malnourished pa-tients who
receive parenteral nutrition if the phosphorus loss is not adequately
corrected. Other causes of hypophosphatemia include prolonged intense
hyperventilation, alcohol withdrawal, poor di-etary intake, diabetic
ketoacidosis, and major thermal burns. Low magnesium levels, low potassium
levels, and hyperparathyroidism related to increased urinary losses of
phosphorus contribute to hypophosphatemia. Respiratory alkalosis can cause a
decrease in phosphorus because of an intracellular shift of phosphorus.
Excess phosphorus binding by antacids containing magne-sium, calcium, or
albumin may decrease the phosphorus available from the diet to amounts below
that required to maintain serum phosphorus balance. The degree of
hypophosphatemia depends on the amount of phosphorus in the diet compared to
the dose of antacid. Vitamin D regulates intestinal ion absorption; there-fore,
a deficiency of vitamin D may cause decreased calcium and phosphorus levels,
which may lead to osteomalacia (softened, brittle bones).
Most of the signs and symptoms of phosphorus deficiency appear to result
from a deficiency of ATP, 2,3-diphosphoglycerate, or both. ATP deficiency
impairs cellular energy resources; diphos-phoglycerate deficiency impairs
oxygen delivery to tissues.
A wide range of neurologic symptoms may occur, such as irri-tability,
fatigue, apprehension, weakness, numbness, paresthesias, confusion, seizures,
and coma. Low levels of diphosphoglycerate may reduce the delivery of oxygen to
peripheral tissues, resulting in tissue anoxia. Hypoxia then leads to an
increase in respiratory rate and respiratory alkalosis, causing phosphorus to
move into the cells and potentiating hypophosphatemia.
It is thought that hypophosphatemia predisposes a person to infection.
In laboratory animals, hypophosphatemia is associated with depression of the
chemotactic, phagocytic, and bacterial ac-tivity of granulocytes.
Muscle damage may develop as the ATP level in the muscle tissue
declines. Clinical manifestations are muscle weakness, muscle pain, and at
times acute rhabdomyolysis (disintegration of striated muscle). Weakness of
respiratory muscles may greatly impair ventilation. Hypophosphatemia also may
predispose a person to insulin resistance and thus hyperglycemia. Chronic loss
of phosphorus can cause bruising and bleeding from platelet dysfunction.
On laboratory analysis,
the serum phosphorus level is less than 2.5 mg/dL (0.80 mmol/L) in adults. When
reviewing laboratory results, the nurse should keep in mind that glucose or
insulin ad-ministration causes a slight decrease in the serum phosphorus level.
PTH levels are increased in hyperparathyroidism. Serum magnesium may decrease
due to increased urinary excretion of magnesium. Alkaline phosphatase is increased
with osteoblastic activity. X-rays may show skeletal changes of osteomalacia or
rickets.
Prevention of
hypophosphatemia is the goal. In patients at risk for hypophosphatemia, serum
phosphate levels should be closely monitored and correction initiated before
deficits become severe. Adequate amounts of phosphorus should be added to
parenteral solutions, and attention should be paid to the phosphorus levels in
enteral feeding solutions.
Severe hypophosphatemia is dangerous and requires prompt attention.
Aggressive IV phosphorus correction is usually limited to patients whose serum
phosphorus levels fall below 1 mg/dL (0.3 mmol/L) and whose GI tract is not
functioning. Possible dan-gers of IV phosphorus administration include tetany from
hypo-calcemia and metastatic calcification from hyperphosphatemia. The rate of
phosphorus administration should not exceed 10 mEq/h, and the site should be
carefully monitored because tissue sloughing and necrosis can occur with
infiltration. In less acute situations, oral phosphorus replacement is usually
adequate.
The nurse identifies
patients at risk for hypophosphatemia and monitors for it. Because malnourished
patients receiving par-enteral nutrition are at risk when calories are introduced
too ag-gressively, preventive measures involve gradually introducing the
solution to avoid rapid shifts of phosphorus into the cells.
For patients with documented hypophosphatemia, careful attention is
given to preventing infection because hypophos-phatemia may alter the
granulocytes. In patients requiring cor-rection of phosphorus losses, the nurse
frequently monitors serum phosphorus levels and documents and reports early
signs of hypophosphatemia (apprehension, confusion, change in level of consciousness).
If the patient experiences mild hypophospha-temia, foods such as milk and milk
products, organ meats, nuts, fish, poultry, and whole grains should be
encouraged. With mod-erate hypophosphatemia, supplements such as Neutra Phos
cap-sules (250 mg phosphorus/capsule) or Fleets Phospho Soda (815 mg phosphorus
/5 mL) may be prescribed (Metheny, 2000).
Related Topics
Privacy Policy, Terms and Conditions, DMCA Policy and Compliant
Copyright © 2018-2023 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.